To evaluate the contribution of cathepsin activity in melanoma and glioblastoma cells, we employed a selective inhibitor targeting cathepsins B, L, and S. First, we assessed the cytotoxicity of the inhibitor on tumor cells by an MTT assay (Figure 8). Here, CTSS is linked to neoplasm.